Cervical cancer vaccine approved
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A cervical cancer vaccine has become the first to receive a European licence, paving the way for an immunisation campaign in Britain. Gardasil could prevent up to 3,000 cases of the disease a year in the UK.
Gardasil, made by the drugs giant Sanofi Pasteur, protects against four strains of the human papillomavirus (HPV), which can cause changes in cells that lead to cervical cancer. The virus is sexually transmitted and up to 80 per cent of women will contract the infection at some stage in their lives.
The vaccine has to be given to girls before they are sexually active. Experts say the best age is nine, but some family campaigners believe the vaccine could trigger unsafe sexual behaviour in teenagers who believe they are protected from other diseases as well.
Cervical cancer kills 274,000 women every year, including 1,120 in the UK. The Joint Committee on Vaccination and Immunisation (JCVI) will review evidence and advise the Department of Health whether Gardasil should be available on the NHS.
A spokeswoman for the department said: "Research has suggested that HP vaccines may provide real benefit. No decisions will be taken until the JCVI present their recommendations to ministers for consideration."
Several companies are developing vaccines. GlaxoSmithKline, which is based in Britain, is hoping for EU approval of its vaccine, Cervarix, within 12 months.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments